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ABSTRACT
Introduction: Besides its critical role in metabolic 
homeostasis, peroxisome proliferator-activated 
receptor (PPAR)-γ modulates several cellular 
responses involved in atherothrombosis. This 
multicenter, double-blind, randomized study 
investigated the effects of two oral hypoglycemic 
agents on markers of inflammation, platelet 
activation, thrombogenesis, and oxidative stress 
in patients with type 2 diabetes. 
Methods and Results: The primary objective of 
this study was to evaluate the effect on C-reactive 
protein (CRP) after a 16-week treatment 
period with either pioglitazone or metformin. 
Additionally, markers of vascular inflammatory 
response, platelet activation, thrombogenesis, 
oxidative stress, glucose, and lipid metabolism, 
as well as liver function, were measured. In total, 
50 patients completed the study. Pioglitazone-
treated patients were found to have statistically 
significantly larger decreases in mean CRP levels 
(–0.4 mg/dL) compared to those treated with 
metformin (–0.2 mg/dL) (P = 0.04), as well as 
greater reductions in levels of mean fasting 
plasma glucose (–27 vs. –9 mg/dL; P = 0.01), 
serum insulin (–2 vs. –1.9 mU/L; P = 0.014), 
homeostatic model assessment (HOMA) (–1.2 
vs. –0.9; P = 0.015), and E-selectin (–12.4 vs. 
+3.4 µg/mL; P = 0.01). Mean glycated hemoglobin 
(HbA1c) levels decreased in both treatment 
groups from baseline to week 16 (–0.4% in the 
pioglitazone group, –0.2% in the metformin 
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vascular cell adhesion molecule 1 [VCAM-1]) 
and the selectin family (P-selectin, E-selectin), 
which are upregulated during atherogenesis [6] 
and elevated in type 2 diabetes [7]. A growing 
body of evidence suggests that inflammatory 
pathways could also be involved in 
microvascular damage, participating in the 
pathogenesis of diabetes complications, such 
as retinopathy and nephropathy [8–9].
Thiazolidinediones (TZDs) can reduce CD40 
ligand (CD40L) serum levels, suggesting an anti-
inflammatory mechanism [10] and a possible 
modulation of platelet aggregation [11]. TZDs 
regulate not only the activity of genes involved 
in glucidic or lipidic metabolism, but also that 
of genes regulating the inflammatory response 
of endothelium, vascular smooth muscle 
cells, T-cells, and monocytes/macrophages [7]. 
Furthermore, peroxisome proliferator-activated 
receptor (PPAR) activation reduces the 
production of inflammatory cytokines and the 
expression and release of metallo-proteases from 
macrophages [12], while in animal models an 
effect of TZDs on oxidative stress production has 
also been reported [13, 14]. 
The anti-inflammatory effect of TZDs 
in patients with type 2 diabetes has been 
reported in several trials [14–20]. However, 
all these studies were designed with different 
endpoints (usually glycemic control), and 
the anti-inflammatory actions of TZD were 
observed only as a secondary outcome. To our 
knowledge, this is the first trial to date designed 
to assess the effect of repeated doses of the TZD, 
pioglitazone, on inflammation, having CRP as 
its principal endpoint. Pioglitazone was studied 
as monotherapy in order to avoid the possible 
interference of other drugs; metformin was 
chosen as a comparator because it is not a TZD 
agent but it does have a profile of action on 
blood glucose and insulin resistance that is as 
similar as possible to that of pioglitazone.
group; P = 0.36). Pioglitazone treatment was 
also found to be associated with a statistically 
significant increase in total cholesterol levels 
(+10 mg/dL in the pioglitazone arm, –3 mg/dL in 
the metformin arm; P = 0.05) and a decrease in 
liver enzyme levels. 
Conclusions: The favorable changes in markers 
of systemic and vascular inflammatory response 
with pioglitazone suggest that it may positively 
influence the atherothrombotic process in 
type 2 diabetes. 
K e y w o r d s :  C a r d i o v a s c u l a r  d i s e a s e ; 
Cardiovascular risk factors; Metformin; Oral 
pharmacologic agents; Pioglitazone; Type 2 
diabetes
INTRODUCTION
Mechanisms underlying the association 
between diabetes and cardiovascular disease 
(CVD) are complex, and include hyperglycemia 
with increased levels of glycosylation 
products, enhanced oxidative stress, and 
inflammation, combined with insulin 
resistance and alterations of lipid metabolism 
[1]. Experimental and epidemiologic evidence 
has highlighted the role of the inflammatory 
cascade in the pathogenesis of atherosclerosis; 
in particular, C-reactive protein (CRP), a 
marker of inflammation, is also a predictor 
of cardiovascular events [2–4]. Considering 
that CRP has a direct proatherogenic effect 
through upregulation of angiotensin II type 1 
receptors and through the stimulation of other 
proinflammatory factors, it is possible that a 
reduction in this parameter obtained either 
through lifestyle changes or drug therapy has 
clinical benefits [5]. Other nonconventional 
markers of cardiovascular risk include adhesion 
molecules of the immunoglobulin superfamily 
(intercellular adhesion molecule 1 [ICAM-1], 
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past medical history of myocardial infarction, 
transient ischemic attacks, or stroke; congestive 
heart failure (New York Heart Association 
class I–IV); significant liver (alanine transaminase 
[ALT] >2.5 upper limit of normal range) or renal 
(serum creatinine >1.2 mg/dL) impairment; 
anemia of any etiology (defined as hemoglobin 
level <10.5 g/dL) or any other clinically relevant 
hematologic disease; diagnosis or suspicion 
of any neoplastic disease; history of chronic 
alcohol or drug/substance abuse, or presence of 
other conditions potentially able to affect study 
subjects’ compliance; concomitant therapy with 
statins, antioxidant drugs (e.g., vitamins, Q10 
coenzyme), beta-blockers, nonsteroidal anti-
inflammatory drugs, aspirin, corticosteroids; 
known allergy, sensitivity, or intolerance to 
study drugs and/or study drugs’ formulation 
ingredients; and participation in another trial 
in the 3 months preceding study entry.
Treatment Interventions
Patients were randomly assigned to receive 
either pioglitazone or metformin. Treatment was 
assigned centrally via telephone after verification 
of the inclusion criteria. The first patient was 
randomly allocated; for each subsequent patient, 
treatment allocation was identified through 
the minimization method, which minimizes 
the imbalance between groups at that time 
according to patient characteristics (center, use 
of angiotensin-converting enzyme inhibitors or 
angiotensin II receptor antagonists).
Pioglitazone 30 mg was taken once daily as a 
starting dose and up-titrated to 45 mg once daily 
in later visits in the case of poor response. The 
control group was treated with metformin, with 
a starting dose of 850 mg/day and up-titrated 
to 850 mg twice or three times a day in later 
visits depending on the glycemic response. 
Study drugs were titrated to higher doses when 
MATERIALS AND METHODS
Study Design
The study was designed as a 16-week, double-
blind, randomized, comparative, multicenter, 
parallel-group trial. After a maximum 1-week 
run-in period, which was necessary to receive 
the results of screening laboratory tests for 
inclusion and exclusion criteria, eligible patients 
were assigned to pioglitazone or metformin. The 
overall treatment period was 16 weeks. In total, 
five clinic visits took place at the start and end of 
the run-in period, and after 4, 8, and 16 weeks 
following randomization. Evaluable patients 
were those who completed at least 8 weeks of 
treatment. The protocol was approved by the 
Ethics Committees of all the participating centers. 
Study Participants
The study was conducted in 10 diabetes clinics. 
Patients of either sex were enrolled, provided they 
met all the following inclusion criteria: diagnosis 
of type 2 diabetes mellitus (defined using the 
American Diabetes Association criteria [21]); 
age 35 and 75 years; glycated hemoglobin 
(HbA1c) levels ≤9.0%; no pharmacologic 
treatment for hyperglycemia in the previous 
3 months; negative response to pregnancy test 
for female patients of childbearing potential; 
cooperative attitude and ability to be trained to 
use the investigational drugs correctly and to 
attain the study procedures; written informed 
consent provided. 
Patients were considered not to be eligible if 
they met one or more of the following exclusion 
criteria: treatment with other oral antidiabetic 
drugs or insulin in the 3 months preceding study 
entry; pregnant or lactating females; presence 
of any disease with malabsorption; acute or 
chronic pancreatitis; familiar polyposis coli; 
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fasting plasma glucose (FPG) was >140 mg/dL; 
in order to maintain the double blind design, 
in the case of up-titration, pioglitazone placebo 
was administered once or twice a day in addition 
to the active pioglitazone tablet. Tablets of each 
investigational study drug, as well as pioglitazone 
placebo, were encapsulated and packed in bottles 
and boxes by the manufacturing contractor 
(Farma Resa S.R.L., Cantù, Italy), according to 
Good Manufacturing Practices.
Efficacy Parameters
The primary efficacy variable was the change 
from baseline in CRP level measured after 
a 16-week treatment period. The secondary 
efficacy variables were the changes from baseline 
in levels of the following parameters: markers 
of inflammatory response (adhesion proteins 
[P-selectin, E-selectin, ICAM-1], interleukin [IL]-6, 
and CD40L); markers of platelet activation and 
thrombogenesis (urinary levels of 11-dehydro 
thromboxaneB2 [TXB2], circulating levels of tissue 
factor (TF), plasminogen activator inhibitor-1; 
markers of oxidative stress (nitrotyrosine); 
standard metabolic (blood glucose, HbA1c, serum 
insulin) and lipidic (total cholesterol, high-
density lipoprotein cholesterol [HDL-C], low-
density lipoprotein cholesterol [LDL-C], very 
low-density lipoprotein cholesterol, triglycerides, 
nonesterified fatty acids) parameters.
All the parameters were centrally measured at 
baseline, and 8 and 16 weeks after randomization, 
with the exception of lipid profile, which was 
evaluated only at baseline and 16 weeks.
Analytical Methods
CRP was measured with a high sensitivity 
nefelometric assay (normal range 0–3 mg/L). The 
soluble forms of CD40L and the endothelium-
derived adhesive molecules, P-selectin, E-selectin, 
ICAM-1, and VCAM-1 were measured in plasma 
using commercially available specific enzyme-
linked immunoassay (ELISA) kits (RD Systems 
and Bender Med Systems, Prodotti Gianni, 
Milano, Italy). The circulating soluble form of TF 
was also measured using a commercial ELISA kit 
(IMUBIND® Tissue Factor, American Diagnostica, 
Intrumentation Laboratory, Milano, Italy). 
TXB2 and 8-iso-prostaglandin F2α markers 
of platelet activation and oxidative stress, 
respectively, were measured in urine collected 
over 24 h. Urinary metabolites were purified 
through sequential extraction on Sep-Pak®
C18 cartridges (Waters Associates and Sep-
Pak® silica cartridges, Waters Associates Waters 
S.p.A., Milano, Italy). The eluates from the 
second extraction were dried, reconstituted in 
phosphate buffer, and frozen at –70°C until 
analysis by specific ELISA (Cayman Chemicals, 
Vinci Biochem, Florence, Italy).
Sample Size
The sample size calculation was based on the 
primary objective of demonstrating a reduction 
in CRP levels induced by pioglitazone as 
opposed to metformin. Based on previous 
evidence on troglitazone [22], the sample size 
was calculated to detect a reduction of 3 mg/L in 
CRP levels in patients treated with pioglitazone 
compared to those receiving metformin, with 
a statistical power of 90% (α = 0.05), and 
assuming a standard deviation in CRP levels of 
3 mg/L. Given these assumptions, a minimum 
of 20 subjects in each arm were needed. It was 
planned to enroll at least 50 individuals to allow 
for a 20% dropout rate.
Statistical Methods
Baseline demographic and background 
data were summarized as percentages for 
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qualitative variables and mean and standard 
deviations or median and interquartile ranges 
for quantitative variables. Categorical variables 
were compared using the Chi-square test. 
Student’s t-test or Mann-Whitney U-test were 
used to compare continuous variables between 
treatment arms.
Within-group changes were tested using 
the paired t-test or the signed rank Wilcoxon 
test. For the assessment of differences between 
treatment groups with respect to primary and 
secondary endpoints, a repeated measures 
analysis of variance (ANOVA) of the change 
from baseline to the end of the study was 
applied using PROC MIXED software (SAS, 
release 9.1; SAS Institute, Cary, NC, USA). 
Continuous variables with substantial 
deviations from the normality assumption were 
mathematically transformed.
Statistical analyses were performed on 
the intention-to-treat population, i.e., all 
randomized patients who received at least one 
dose of study medication and who completed at 
least 8 weeks of treatment.
RESULTS
Overall, 67 patients were initially identified, 
of whom 9 were not randomized (Fig. 1). Of 
the 58 patients randomized (29 assigned to 
pioglitazone and 29 to metformin), 8 (5 assigned 
to pioglitazone and 3 to metformin) prematurely 
discontinued the study. Therefore, 50 patients 
completed the entire study period and were 
considered for all the efficacy analyses (24 in 
the pioglitazone group and 26 in the metformin 
group). Baseline patient characteristics according 
to allocated treatment are reported in Table 1 
and show that the two groups were well matched 
for all the variables investigated. Results relative 
to all efficacy and safety laboratory parameters 
are reported in Table 2.
Primary Efficacy Variable: CRP
A statistically significant decrease from baseline 
to week 16 was observed in the CRP levels of 
patients treated with pioglitazone (P < 0.001), 
compared to a smaller and nonsignificant 
decrease in those treated with metformin. The 
comparison between treatments showed a 
statistically significant difference (P = 0.04) in 
favor of pioglitazone.
Secondary Efficacy Variables
A statistically significant decrease from baseline to 
week 16 in E-selectin levels (P < 0.05) was observed 
in patients treated with pioglitazone compared to 
no changes in patients treated with metformin. 
The comparison between treatments showed 
a statistically significant difference in favor of 
pioglitazone for E-selectin levels (P = 0.01).
No statistically significant changes in markers 
of platelet activation and thrombogenesis, or 
nitrotyrosine levels, were observed with either 
treatment. 
Fig. 1  Study ow diagram
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Worsening of comorbid 
conditions (2)
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Table 1  Patient baseline characteristics according to study group
Characteristic Pioglitazone Metformin P value
Number of patients 29 29
Age (years) 59.1±6.8 56.4±7.9 0.17
Gender:
Males 14 (48.3%) 19 (65.5%) 0.18
Females 15 (51.7%) 10 (34.5%) –
BMI (kg/m2) 31.1±3.2 31.7±3.6 0.52
Weight (kg) 84.1±12.5 87.8±11.5 0.24
Smoking (cigarettes/day): 24 (82.8%) 22 (75.9%) 0.70
0
<10 1 (3.4%) 2 (6.9%) –
10–20 2 (6.9%) 1 (3.4%) –
>20 2 (6.9%) 4 (13.8%) –
Diabetes duration (years) 4.4±3.2 3.9±2.2 0.50
CRP (mg/L) 1.9 (1.1–5.3) 2.2 (1.4–3.0) 0.86
FPG (mg/dL) 152±38 146±46 0.55
HbA1c (%) 6.9±0.8 6.8±0.7 0.42
Insulin (mU/L) 9.1 (6.9–14.3) 10.4 (6.7–12.9) 0.96
HOMA index 3.3 (2.4–5.4) 3.5 (2.0–4.7) 0.65
Total cholesterol (mg/dL) 215±24 214±34 0.89
HDL-C (mg/dL) 40±10 39±9 0.66
LDL-C (mg/dL) 145±27 144±29 0.93
VLDL-C (mg/dL) 23 (18–35) 28 (21–36) 0.45
FFA (mmol/L) 0.4 (0.3–0.5) 0.4 (0.3–0.5) 0.61
Triglycerides (mg/dL) 115 (90–167) 138 (104–182) 0.45
P-selectin (μg/mL) 38.9 (21.9–90.0) 41.8 (31.2–62.1) 0.96
E-selectin (μg/mL) 70.8 (53.9–79.6) 65.3 (59.1–82.7) 0.80
ICAM-1 (μg/mL) 290 (232–324) 253 (230–296) 0.42
CD40L (pg/mL) 1.5 (0.5–2.4) 1.2 (0.8–2.2) 0.70
TXB2 (pg/mg creatinine) 144 (75–207) 122 (85–284) 0.77
TF (pg/mL) 114 (102–149) 145 (108–180) 0.26
PAI-1 (ng/mL) 52.0 (24.5–78.6) 33.1 (24.7–81.7) 0.65
Nitrotyrosine (nM) 6.7±1.5 6.5±1.4 0.77
For continuous variables values are mean ± standard deviation or median and range 
BMI body mass index, CD40L CD40 ligand, CRP C-reactive protein, FFA free fatty acid, FPG fasting plasma glucose, 
HbA1c glycated hemoglobin, HDL-C high-density lipoprotein cholesterol, HOMA homeostatic model assessment, ICAM-1 
intercellular adhesion molecule-1, LDL-C low-density lipoprotein cholesterol, PAI-1 plasminogen activator inhibitor-1,  
TF tissue factor, TXB2 11-dehydro thromboxaneB2, VLDL-C very low-density lipoprotein cholesterol 
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Number of patients 24 24 26 26 –
Markers of inammatory response
CRP (mg/L) 1.8 (1.1–4.7) 1.4 (0.5–2.5)* 2.0 (1.1–2.9) 1.8 (0.8–3.7) 0.04
P-selectin (μg/mL) 56.9 (26.7–140) 52.2 (29.3–126.8) 41.3 (31.2–68.1) 47.5 (29.2–74.1) 0.73
E-selectin (μg/mL) 70.2 (52.6–81.5) 57.8 (53.7–83.8)** 65.1 (59.1–79.9) 68.5 (62.9–78.3) 0.01
ICAM-1 (μg/mL) 292 (233–322) 269 (241–312) 251 (230–296) 252 (215–309) 0.87
CD40L (pg/mL) 1.6 (0.5–2.9) 2.0 (0.4–3.6) 1.3 (0.8–2.5) 1.4 (0.8–2.4) 0.98
Markers of platelet activation and thrombogenesis
TXB2 (pg/mg creatinine) 146 (82–221) 121 (87–198) 123 (85–304) 159 (106–191) 0.61
TF (pg/mL) 113 (102–131) 139 (113–172) 141 (100–189) 145 (111–223) 0.23
PAI-1 (ng/mL) 55.1 (21.0–82.4) 35.8 (23.8–66.1) 32.7 (24.3–81.7) 39.5 (31.7–46.2) 0.69
Markers of oxidative stress
Nitrotyrosine (nM) 6.7±1.5 6.6±1.6 6.5±1.4 6.3±1.0 0.82
Glucose parameters
FPG (mg/dL) 153±40 126±25*** 144±47 135±48* 0.01
HbA1c (%) 6.9±0.9 6.5±0.8** 6.7±0.7 6.5±0.7* 0.36
Insulin (mU/L) 8.3 (6.7–14.7) 6.3 (4.7–9.2)*** 10.0 (5.3–12.8) 8.1 (5.6–10.6) 0.014
HOMA index 3.2 (2.1–5.4) 2.0 (1.3–2.9)*** 3.2 (2.0–4.1) 2.3 (2.1–3.3) 0.015
Lipid parameters
Total cholesterol (mg/dL) 212±24 222±35** 215±35 212±35 0.05
HDL-C (mg/dL) 41±10 45±11* 40±9 42±9*** 0.19
LDL-C (mg/dL) 141±26 148±34 147±29 142±27 0.07
VLDL-C (mg/dL) 22.8 (18.2–33.5) 23.8 (16.0–32.2) 24.3 (17.4–36.4) 26.4 (17.8–37.2) 0.94
FFA (mmol/L) 0.4 (0.3–0.5) 0.4 (0.2–0.5) 0.4 (0.3–0.5) 0.4 (0.3–0.6) 0.07
Triglycerides (mg/dL) 114 (91–168) 119 (80–161) 122 (87–182) 132 (89–186) 0.94
Safety parameters
Hemoglobin (g/dL) 14.4±1.1 14.1±1.0 14.6±1.0 14.4±1.1 0.58
WBCs (109/L) 6.2±1.5 5.9±1.4** 6.5±1.9 6.3±1.7 0.60
Neutrophils (%) 51.4±8.0 50.2±7.2 53.5±7.8 53.7±9.3 0.72 
ALT (U/L) 26.5 (20.5–33.0) 19.0 (17.0–23.5)*** 28.0 (23.0–48.0) 27.5 (23.0–46.0) <0.0001
AST (U/L) 20.0 (18.0–23.0) 18.5 (15.0–22.0)* 20.0 (17.0–24.0) 21.0 (16.0–26.0) 0.003
γGT (U/L) 28.0 (21.0–36.5) 19.5 (14.0–26.5)*** 35.5 (24.0–40.0) 32.0 (23.0–40.0) <0.0001
Values are mean ± standard deviation or median and range
ALT alanine transaminase, AST aspartate transaminase, CD40L CD40 ligand, CRP C-reactive protein, FFA free fatty acid, 
FPG fasting plasma glucose, γGT γ glutamyl transpeptidase, HbA1c glycated hemoglobin, HDL-C high-density lipoprotein 
cholesterol, HOMA homeostatic model assessment, ICAM-1 intercellular adhesion molecule-1, LDL-C low-density 
lipoprotein cholesterol, PAI-1 plasminogen activator inhibitor-1, TF tissue factor, TXB2 11-dehydro thromboxaneB2, 
VLDL-C very low-density lipoprotein cholesterol, WBCs white blood cells
* P < 0.01 vs. baseline; ** P < 0.05 vs. baseline; *** P < 0.001 vs. baseline
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A statistically significant decrease from baseline 
to week 16 in levels of FPG (P < 0.001), HbA1c
(P < 0.05), insulin (P < 0.001), and homeostatic 
model assessment (HOMA) index (P < 0.001) was 
observed in patients treated with pioglitazone, 
while patients on metformin had a significant 
decrease from baseline to week 16 in levels of FPG 
(P < 0.01) and HbA1c (P < 0.01). The comparison 
between treatments showed a statistically 
significant difference in favor of pioglitazone for 
levels of FPG (P = 0.01), insulin (P = 0.014), and 
HOMA index (P = 0.015), but not for HbA1c.
A statistically significant increase from 
baseline to week 16 in levels of total cholesterol 
(P < 0.05) and HDL-C (P < 0.01) was observed 
in patients treated with pioglitazone, whereas 
in those receiving metformin there was a 
statistically significant increase from baseline 
to week 16 in HDL-C levels (P < 0.001) without 
any modification in total cholesterol levels. 
The comparison between treatments showed 
a statistically significant difference for total 
cholesterol in favor of metformin (P = 0.05).
Safety
A total of 39 adverse events (AEs) were reported; 
23 in patients treated with pioglitazone and 
16 in patients treated with metformin. In total, 
17 AEs (11 in patients treated with pioglitazone 
and 6 in patients treated with metformin) 
were considered to be adverse drug reactions, 
i.e., those with a certain, probable, or possible 
correlation with study drug. Four hypoglycemic 
episodes were reported in the pioglitazone group 
and none in the metformin group. No serious 
AEs were reported with either treatment. Only 
one AE (acute bronchitis) in a patient treated 
with metformin was of severe intensity, but was 
not considered to be related to study drug. 
Six patients, four treated with pioglitazone 
and two with metformin, discontinued the study 
due to AEs. Causes of early discontinuations 
in patients treated with pioglitazone were 
hypoglycemia in two patients, general 
discomfort, vomiting, and diarrhea in one 
patient, and abdominal pain in another patient. 
In the metformin group, myocardial ischemia 
in one patient and flatulence in another were 
responsible for discontinuations.
Laboratory Safety Parameters
The results of hematology tests at baseline and 
week 16 showed a statistically significant decrease 
from baseline in white blood cell counts (P < 0.05) 
in patients treated with pioglitazone. No 
substantial changes from baseline in hemoglobin 
and neutrophil levels were observed with 
either treatment. The comparison between 
treatments in hematology parameters did 
not show statistically significant differences for 
any variable.
The results of liver function enzyme tests 
at baseline and week 16 showed a statistically 
significant decrease from baseline in levels of 
ALT (P < 0.001), aspartate transaminase (AST) 
(P < 0.01), and γ glutamyl transpeptidase (GT) 
levels (P < 0.001) in patients treated with 
pioglitazone, with no substantial changes in 
any variable in patients treated with metformin. 
The comparison between treatments showed 
a statistically significant difference in favor of 
pioglitazone for levels of ALT (P < 0.0001), AST 
(P = 0.003), and γGT (P < 0.0001).
DISCUSSION
It is increasingly recognized that markers 
of vascular inflammation play a role in the 
pathogenesis of type 2 diabetes, insulin resistance, 
and atherosclerosis [11, 23]; CRP in particular 
is an independent predictor of both type 2 
diabetes and CVD [4, 24]. The clinical relevance 
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of lowering CRP values in terms of reducing 
major adverse cardiac events and mortality has 
been clearly demonstrated in clinical trials of 
statins [25, 26]. Previous studies have shown 
that PPAR-γ agonists may affect inflammatory 
pathways via transcriptional mechanisms, and 
decreases in cytokines, chemokines, and matrix 
metallo-proteinases have been demonstrated in 
monocytes/macrophages, T-cells, and vascular 
smooth muscle cells (VSMC) [27]. TZDs have 
been associated with an antiatherogenic effect, 
which cannot be completely accounted for by 
the observed improvement in glycemic control. 
In fact, in comparisons with sulfonylureas, the 
TZD, pioglitazone, has shown beneficial effects 
on intima-media thickness [28] and on the 
progression of coronary atherosclerosis [29], 
which are evident after a relatively short 
follow-up. Based on these observations, 
it can be speculated that the reduction in 
major cardiovascular events reported in the 
PROspective pioglitAzone Clinical Trial In 
macroVascular Events (PROactive) study [30] 
and confirmed by meta-analyses, including all 
available pioglitazone trials [31–32], is partly due 
to some extraglycemic action of the drug.
The anti-inflammatory effect of TZDs is a 
good candidate as a potential antiatherogenic 
mechanism independent of any glucose-
lowering action. A reduction in levels of markers 
of inflammation induced by pioglitazone has 
been reported in previous experimental studies 
and clinical trials [10–20]. However, in previous 
clinical observations, its anti-inflammatory 
activity has been reported in comparisons with 
placebo or other glucose-lowering, noninsulin-
sensitizing drugs. Therefore, on the basis of 
available data, it was not possible to distinguish 
between the specific effects of the drug and the 
effects induced by the improvement in glucose 
control and/or insulin sensitivity. The present 
study is the first to consider inflammation 
as the principal endpoint, excluding any 
concomitant treatments capable of interfering 
with the anti-inflammatory effects of the 
experimental drug. Interestingly, pioglitazone 
monotherapy produced a greater reduction 
in CRP levels than did metformin, which also 
has an insulin sensitizing effect despite sharing 
a similar overall glycemic control. It should 
be recognized that the effect of pioglitazone 
on insulin sensitivity was greater than that of 
metformin, meaning that theoretically, some 
of the differences between the two treatments 
could be related to the greater enhancement of 
insulin action. A beneficial effect of pioglitazone 
in reducing CRP in diabetic patients with high 
levels of this protein and high cardiovascular 
risk has been reported [33]. In the present 
study, the authors were able to show that in 
diabetic patients at low risk for cardiovascular 
disease, this beneficial (CRP-lowering) effect 
was superior to that achieved with metformin. 
The lack of any significant effect of treatment 
on platelet activity and on markers of platelet 
activation and thrombogenesis is inconsistent 
with previous studies [11, 34]. This result could 
be explained by the fact that in the present trial, 
the patients enrolled were drug-naïve and they 
had relatively moderate hyperglycemia. It is 
possible that some of the previously described 
benefits of TZD treatment on these parameters 
were related to the improvement in blood 
glucose in patients with a greater degree of 
impairment in metabolic control. 
In this study, pioglitazone treatment was 
found to be associated with a statistically 
significant increase in total cholesterol and 
HDL-C levels. It is well recognized that 
pioglitazone positively affects the lipid profile 
by increasing HDL-C and reducing trigycerides. 
The effect on total cholesterol is less clear but 
a recent meta-analysis reported that treatment 
with this drug was associated with a significant 
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reduction in total cholesterol [35]. Furthermore, 
it is known that pioglitazone modifies LDL 
particle size, reducing its atherogenic effects [36]. 
Recently, a post-hoc analysis of the PROactive 
study showed that the beneficial effect of 
pioglitazone on cardiovascular outcome was 
mainly due to an increase in HDL-C, rather than 
an amelioration of HbA1c [37].
In our study, pioglitazone treatment 
significantly decreased levels of liver enzymes. 
The positive effect of pioglitazone on liver 
enzymes and nonalcoholic fatty liver disease 
(NAFLD) is well known and our results confirm 
this effect. A recent meta-analysis showed 
that in patients with NAFLD, pioglitazone 
improved histologic disease activity, slowed 
fibrosis progression, and extensively ameliorated 
cardiometabolic endpoints [38].
Metformin is recognized by almost all available 
guidelines and treatment recommendations 
as the drug of choice for patients newly 
diagnosed with type 2 diabetes [39–42]. 
Obviously, such a position, which is based 
on an overall assessment of short- and long-
term efficacy, tolerability, safety, and cost data 
cannot be modified by any single study showing 
the superiority of another drug with respect 
to a parameter other than a hard endpoint. 
Furthermore, it is not possible to anticipate the 
long-term effects associated with a reduction 
in CRP levels of the magnitude detected in 
our study, although the association between 
the levels of this marker and cardiovascular 
risk appears to be linear [43]. Only long-
term, large-scale trials specifically designed 
for cardiovascular outcomes can provide 
reliable information on the effects of drugs on 
cardiovascular risk. However, such trials are 
unavailable at the present time for most of the 
agents currently used in the treatment of type 2 
diabetes. This study suggests that alternative 
parameters (other than glucose control), that 
are diversely affected by glucose-lowering drugs, 
should be considered in the overall assessment 
of treatments. Moreover, the positive effects of 
the two drugs investigated in the present trial 
on inflammatory and metabolic parameters 
could be regarded as useful consequences in the 
treatment of type 2 diabetic patients. Recently, 
a retrospective cohort study using data from the 
UK-based General Practice Research Database 
showed that a combination of metformin plus 
pioglitazone appeared to provide superior clinical 
outcomes compared with the most commonly 
used regimen, represented by the association of 
metformin with a sulfonylurea [44]. 
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